To evaluate the efficacy of Rohitakadi vati and Pippali vati orally after Virechana in Non alcoholic fatty liver disease

Phase 2

• Conditions: Health Condition 1: E889- Metabolic disorder, unspecified

• Registration Number: CTRI/2024/07/070476
• Lead Sponsor: Dr Harshitha K, S

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Clinical signs and symptoms suggesting of NAFLD/Yak?t Roga, that is, pain in right upper quadrant/epigastric region of the abdomen, feeling of nausea, and vomiting, loss of appetite, burning sensation in the abdomen

2.Ultrasonography (USG) abdomen/or other scanning modalities such as contrast-enhanced computed tomography (CECT) abdomen showing fatty infiltration of the liver. USG findings suggestive of fatty liver grade 1, 2, and 3

3.Biochemical: Liver function tests showing raised alanine transaminases (ALT) levels approximately more than 1.5 times the normal limits with/without raised lipid profile and fasting blood glucose levels within normal limits.

Exclusion Criteria

1.Patients in whom alcohol intake exceeded 20 g/day (history of alcohol intake was taken separately from the patients and close relatives)

2.Patients having fasting blood sugar (FBS) =200 mg/dl and postprandial blood sugar (PPBS) =250 mg/dl, despite taking oral hypoglycemic agents, Stage II hypertension, i.e.,systolic blood pressure =160mmHg and diastolic blood pressure =100 mmHg, despite taking antihypertensive drugs

3.Patients with complications of metabolic syndrome such as a cerebrovascular accident, myocardial infarction, chronic kidney disease, suffering from cirrhosis, ascites, variceal hemorrhage, coagulopathy, hepatorenal syndrome, consuming hepatotoxic medicines, alcohol or other narcotic substances.

Study & Design

• Study Type: Interventional
• Study Design: Not specified